Abstract
Lilly is developing LY-354740, the lead compound in a series of derivatives of the metabotropic glutamate receptor group II agonist L-CCG-1, for the potential treatment of anxiety [212536], [276941], [276942].
MeSH terms
-
Animals
-
Anti-Anxiety Agents / pharmacokinetics
-
Anti-Anxiety Agents / pharmacology*
-
Anti-Anxiety Agents / therapeutic use
-
Anxiety Disorders / drug therapy
-
Bridged Bicyclo Compounds / pharmacokinetics
-
Bridged Bicyclo Compounds / pharmacology*
-
Bridged Bicyclo Compounds / therapeutic use
-
Clinical Trials as Topic
-
Excitatory Amino Acid Agonists / pharmacokinetics
-
Excitatory Amino Acid Agonists / pharmacology*
-
Excitatory Amino Acid Agonists / therapeutic use
-
Humans
-
Receptors, Metabotropic Glutamate / antagonists & inhibitors
Substances
-
Anti-Anxiety Agents
-
Bridged Bicyclo Compounds
-
Excitatory Amino Acid Agonists
-
Receptors, Metabotropic Glutamate
-
eglumetad